Herein the new CXCR4 antagonist Pep R strengthen anti-PD-1 efficacy in two murine cancer models, MC38 colon cancer and B16-hCXCR4 melanoma, respectively reported to be immune responsive [21] and immune resistant cancer models [22, 24]. Here, PDCD1 is linked to cancer.